

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTALAB1643

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

- NEWS 1 Web Page for STN Seminar Schedule - N. America
 - NEWS 2 JAN 02 STN pricing information for 2008 now available
 - NEWS 3 JAN 16 CAS patent coverage enhanced to include exemplified prophetic substances
 - NEWS 4 JAN 28 USPATFULL, USPAT2, and USPATOLD enhanced with new custom IPC display formats
 - NEWS 5 JAN 28 MARPAT searching enhanced
 - NEWS 6 JAN 28 USGENE now provides USPTO sequence data within 3 days of publication
 - NEWS 7 JAN 28 TOXCENTER enhanced with reloaded MEDLINE segment
 - NEWS 8 JAN 28 MEDLINE and LMEDLINE reloaded with enhancements
 - NEWS 9 FEB 08 STN Express, Version 8.3, now available
 - NEWS 10 FEB 20 PCI now available as a replacement to DPCI
 - NEWS 11 FEB 25 IFIREF reloaded with enhancements
 - NEWS 12 FEB 25 IMSPRODUCT reloaded with enhancements
 - NEWS 13 FEB 29 WPINDEX/WPIDS/WPIX enhanced with ECLA and current U.S. National Patent Classification
 - NEWS 14 MAR 31 IFICDB, IFIPAT, and IFIUDB enhanced with new custom IPC display formats
 - NEWS 15 MAR 31 CAS REGISTRY enhanced with additional experimental spectra
 - NEWS 16 MAR 31 CA/CAplus and CASREACT patent number format for U.S. applications updated
 - NEWS 17 MAR 31 LPCI now available as a replacement to LDPCI
 - NEWS 18 MAR 31 EMBASE, EMBAL, and LEMBASE reloaded with enhancements
 - NEWS 19 APR 04 STN AnaVist, Version 1, to be discontinued
- NEWS EXPRESS FEBRUARY 08 CURRENT WINDOWS VERSION IS V8.3,
AND CURRENT DISCOVER FILE IS DATED 20 FEBRUARY 2008

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items
NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

***** STN Columbus *****

FILE 'HOME' ENTERED AT 18:33:27 ON 12 APR 2008

=> file caplus

COST IN U.S. DOLLARS	ENTRY	SINCE FILE SESSION	TOTAL
FULL ESTIMATED COST		0.21	0.21

FILE 'CAPLUS' ENTERED AT 18:33:43 ON 12 APR 2008

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications.

The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 12 Apr 2008 VOL 148 ISS 16
FILE LAST UPDATED: 11 Apr 2008 (20080411/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s "single chain diabody" and library and linker

1409735 "SINGLE"

3379 "SINGLES"

1412605 "SINGLE"

("SINGLE" OR "SINGLES")

760502 "CHAIN"

331139 "CHAINS"

955504 "CHAIN"

("CHAIN" OR "CHAINS")

240 "DIABODY"

188 "DIABODIES"

325 "DIABODY"

("DIABODY" OR "DIABODIES")

34 "SINGLE CHAIN DIABODY"

("SINGLE"(W)"CHAIN"(W)"DIABODY")

87847 LIBRARY

31499 LIBRARIES

103475 LIBRARY

(LIBRARY OR LIBRARIES)

24446 LINKER

5963 LINKERS

27941 LINKER

(LINKER OR LINKERS)

L1 1 "SINGLE CHAIN DIABODY" AND LIBRARY AND LINKER

=> d L1 bib abs 1

L1 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2004:610406 CAPLUS

DN 141:330525

TI Recombinant bispecific antibodies for the targeting of adenoviruses to
CEA-expressing tumour cells: a comparative analysis of bacterially
expressed single-chain diabody and tandem
scFv

AU Korn, Tina; Nettelbeck, Dirk M.; Voelkel, Tina; Mueller, Rolf; Kontermann,
Roland E.

CS Institut fuer Molekularbiologie und Tumorforschung, Philipps-Universitaet,
Marburg, 35033, Germany

SO Journal of Gene Medicine (2004), 6(6), 642-651

CODEN: JGMEFG; ISSN: 1099-498X

PB John Wiley & Sons Ltd.

DT Journal

LA English

AB We have generated two distinct recombinant bispecific antibody mols. for
the retargeting of adenoviral vectors to CEA-expressing tumor cells.

These antibody mols. were produced by combining the antigen-binding sites

of a neutralizing anti-fiber knob scFv (S11) and an anti-CEA antibody either in a single-chain diabody format (scDb CEA-S11) or a tandem scFv format (taFv CEA-S11). In order to facilitate expression of taFv CEA-S11 in bacteria we selected from a phage display library taFv mols. with an optimized linker that connects the two scFv fragments. ScDb CEA-S11 and taFv CEA-S11 were expressed and purified in sol. form from the bacterial periplasm with yields of approx. 100 .mu.g per L of bacterial culture. In vitro, both bispecific mols. mediated selective and enhanced transduction of CEA-expressing tumor cells by recombinant adenoviruses. These assays did not reveal any differences in efficiency of adenoviral transduction by the two antibody formats. However, compared with taFv CEA-S11, scDb CEA-S11 exhibited a 2- to 3-fold increased stability in human plasma at 37.degree.C. In summary, we could demonstrate that both formats are suitable for adenovirus targeting to tumor cells with similar biol. activity in vitro.

RE.CNT 49 THERE ARE 49 CITED REFERENCES AVAILABLE FOR THIS RECORD

ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> s (single chain) and diabody and linker and library

1409735 SINGLE

3379 SINGLES

1412605 SINGLE

(SINGLE OR SINGLES)

760502 CHAIN

331139 CHAINS

955504 CHAIN

(CHAIN OR CHAINS)

14157 SINGLE CHAIN

(SINGLE(W)CHAIN)

240 DIABODY

188 DIABODIES

325 DIABODY

(DIABODY OR DIABODIES)

24446 LINKER

5963 LINKERS

27941 LINKER

(LINKER OR LINKERS)

87847 LIBRARY

31499 LIBRARIES

103475 LIBRARY

(LIBRARY OR LIBRARIES)

L2 5 (SINGLE CHAIN) AND DIABODY AND LINKER AND LIBRARY

=> duplicate remove L2

PROCESSING COMPLETED FOR L2

L3 5 DUPLICATE REMOVE L2 (0 DUPLICATES REMOVED)

=> d L3 bib abs 1-5

L3 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2005:1171482 CAPLUS

DN 143:438502

TI Diabodies specific to Streptococcus surface antigen I/II for
diagnosis and treatment of oral disease such as periodontitis and dental
caries

IN Finnern, Ricarda; Fischer, Rainer

PA Fraunhofer-Gesellschaft Zur Foerderung der Angewandten Forschung e.v.,
Germany

SO PCT Int. Appl., 54 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------

PI WO 2005103085	A1	20051103	WO 2005-EP4284	20050421
------------------	----	----------	----------------	----------

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ,
LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA,
NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL,
SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA,
ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT,
RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML,
MR, NE, SN, TD, TG

EP 1749030	A1	20070207	EP 2005-742967	20050421
------------	----	----------	----------------	----------

R: CH, DE, FR, GB, LI

JP 2008507258	T	20080313	JP 2007-508847	20050421
---------------	---	----------	----------------	----------

KR 2007038454	A	20070410	KR 2006-724400	20061121
---------------	---	----------	----------------	----------

US 20070231321	A1	20071004	US 2007-578641	20070320
----------------	----	----------	----------------	----------

PRAI US 2004-564396P P 20040422

WO 2005-EP4284	W	20050421		
----------------	---	----------	--	--

AB Common oral diseases such as periodontitis and dental caries can be
prevented effectively by passive immunization. The present invention
provides human single chain Fv (scFv) and
diabody antibody fragments based on the binding characteristics of

the murine monoclonal antibody Guy's 13. Like the parent antibody, these derivs. bind specifically to SAI/II, the surface adhesin of Streptococcus and the human diabody deriv. is capable of aggregating streptococcal cells, making it a useful candidate therapeutic agent for passive immunization against oral diseases.

RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2005:45536 CAPLUS

DN 142:196175

TI A diabody that dissociates to monomer forms at low concentration: effects on binding activity and tumor targeting

AU Huang, Bao-cheng; Foote, Linda J.; Lankford, Trish K.; Davern, Sandra M.; McKeown, Cathy K.; Kennel, Stephen J.

CS Life Sciences Division, Oak Ridge National Laboratory, Oak Ridge, TN, USA

SO Biochemical and Biophysical Research Communications (2005), 327(4), 999-1005

CODEN: BBRC9; ISSN: 0006-291X

PB Elsevier

DT Journal

LA English

AB A human scFv, 15-9, was selected from a phage display library for binding to murine laminin-1. A diabody was made from the scFv by shortening the linker from 15 to 5 amino acids between the VH and VL sequence. Radioiodinated scFv and diabody were analyzed for size, binding to laminin, and biodistribution in tumor bearing mice. Diabody prepns. at concns. greater than 10 nM were largely dimer forms (.apprx.60 kDa) as judged by gel filtration, but dild. diabody was eluted as a monomer (.apprx.30 kDa). At low concns. the radiolabeled diabody did not bind well to laminin. The ¹²⁵I diabody had significantly lower accumulation in tumors than did the scFv when injected at lower concns. These data indicate that the diabody dimer dissocs. at concns. of about 10 nM resulting in monomers with no binding activity for laminin and poor tumor homing properties.

RE.CNT 30 THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS RECORD

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2004:252106 CAPLUS

DN 140:269512

TI Multivalent and multispecific engineered antibodies

IN Holliger, Kaspar-philipp; Griffiths, Andrew David; Hoogenboom, Hendricus

Renerus J. M.; Malmqvist, Magnus; Marks, James David; McGuinness, Brian Timothy; Pope, Anthony Richard; Prospero, Terence Derek; Winter, Gregory Paul

PA Medical Research Council, UK

SO U.S. Pat. Appl. Publ., 98 pp.

CODEN: USXXCO

DT Patent

LA English

FAN.CNT 4

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 20040058400	A1	20040325	US 2002-247839	20020920
US 7122646	B2	20061017		
WO 9413804	A1	19940623	WO 1993-GB2492	19931203
W: AT, AU, BB, BG, BR, BY, CA, CH, CZ, DE, DK, ES, FI, GB, HU, JP, KP, KR, KZ, LK, LU, LV, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SK, UA, US, UZ, VN				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
US 5837242	A	19981117	US 1996-448418	19960514
US 6492123	B1	20021210	US 1998-146979	19980903
PRAI GB 1992-25453	A	19921204		
GB 1993-816	A	19930116		
EP 1993-303614	A	19930510		
GB 1993-19969	A	19930922		
WO 1993-GB2492	W	19931203		
US 1996-448418	A1	19960514		
US 1998-146979	A1	19980903		

AB The authors disclose antibody constructs comprising a first heavy chain variable region and a second light chain variable region, the domains being linked but incapable of assocg. with each other to form an antigen binding site. These constructs assoc. to form antigen binding multimers, such as dimers, which may be multivalent or have multispecificity. The domains may be linked by a short peptide linker or may be joined directly together. Bispecific dimers may have longer linkers. Methods of prepn. of the polypeptides and multimers and diverse repertoires thereof, and their display on the surface of bacteriophage for easy selection of binders of interest, are disclosed, along with many utilities.

L3 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2004:610406 CAPLUS

DN 141:330525

TI Recombinant bispecific antibodies for the targeting of adenoviruses to CEA-expressing tumour cells: a comparative analysis of bacterially expressed single-chain diabody and tandem

scFv

AU Korn, Tina; Nettelbeck, Dirk M.; Voelkel, Tina; Mueller, Rolf; Kontermann, Roland E.

CS Institut fuer Molekularbiologie und Tumorforschung, Philipps-Universitaet, Marburg, 35033, Germany

SO Journal of Gene Medicine (2004), 6(6), 642-651

CODEN: JGMEFG; ISSN: 1099-498X

PB John Wiley & Sons Ltd.

DT Journal

LA English

AB We have generated two distinct recombinant bispecific antibody mols. for the retargeting of adenoviral vectors to CEA-expressing tumor cells. These antibody mols. were produced by combining the antigen-binding sites of a neutralizing anti-fiber knob scFv (S11) and an anti-CEA antibody either in a single-chain diabody format (scDb CEA-S11) or a tandem scFv format (taFv CEA-S11). In order to facilitate expression of taFv CEA-S11 in bacteria we selected from a phage display library taFv mols. with an optimized linker that connects the two scFv fragments. ScDb CEA-S11 and taFv CEA-S11 were expressed and purified in sol. form from the bacterial periplasm with yields of approx. 100 .mu.g per L of bacterial culture. In vitro, both bispecific mols. mediated selective and enhanced transduction of CEA-expressing tumor cells by recombinant adenoviruses. These assays did not reveal any differences in efficiency of adenoviral transduction by the two antibody formats. However, compared with taFv CEA-S11, scDb CEA-S11 exhibited a 2- to 3-fold increased stability in human plasma at 37.degree.C. In summary, we could demonstrate that both formats are suitable for adenovirus targeting to tumor cells with similar biol. activity in vitro.

RE.CNT 49 THERE ARE 49 CITED REFERENCES AVAILABLE FOR THIS RECORD

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2002:185179 CAPLUS

DN 136:215405

TI A single-chain antibody to human endoglin for use in the prevention of tumor vascularization

IN Kontermann, Roland; Miller, Daniel; Mueller, Rolf

PA Vectron Therapeutics AG, Germany

SO PCT Int. Appl., 37 pp.

CODEN: PIXXD2

DT Patent

LA German

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------

PI WO 2002020614 A2 20020314 WO 2001-EP10197 20010904
WO 2002020614 A3 20020801
W: CA, JP, US
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL,
PT, SE, TR
DE 10043481 A1 20020411 DE 2000-10043481 20000904
CA 2421202 A1 20030304 CA 2001-2421202 20010904
EP 1315760 A2 20030604 EP 2001-980336 20010904
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, FI, CY, TR
JP 2004508035 T 20040318 JP 2002-525233 20010904
US 20040053329 A1 20040318 US 2003-363349 20030801
PRAI DE 2000-10043481 A 20000904
WO 2001-EP10197 W 20010904

AB A single-chain antibody that specifically binds to the extracellular domain of the human endoglin (CD105 antigen) is described for use in the prevention of angiogenesis of tumors. The antibody was identified by screening a phage display library. A fusion protein of the antibody with an antibody to the knob protein of adenovirus 5 is prep'd. for use in the targeting of adenoviral gene therapy vectors to endothelial cells. Other uses for the antibody, including the use of fusion proteins with anti-CD3 antibodies to induce lysis of endothelial cells.